The Association Between Statin Use and Risk of Chronic Kidney Disease in Community-Dwelling Older People in Shanghai, China

References

• Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011;80(1):17–28. doi:10.1038/ki.2010.483
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081. doi:10.1016/S0140-6736(10)60674-5
   PubMed Web of Science ®Google Scholar
• van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341–1352. doi:10.1038/ki.2010.536
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80(1):93–104. doi:10.1038/ki.2010.531
   PubMed Web of Science ®Google Scholar
• Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331–1340. doi:10.1038/ki.2010.550
   PubMed Web of Science ®Google Scholar
• Fraser SD, Aitken G, Taal MW, et al. Exploration of chronic kidney disease prevalence estimates using new measures of kidney function in the health survey for England. PLoS One. 2015;10(2):e0118676. doi:10.1371/journal.pone.0118676
   Web of Science ®Google Scholar
• James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010;375(9722):1296–1309. doi:10.1016/S0140-6736(09)62004-3
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822. doi:10.1016/S0140-6736(12)60033-6
   PubMed Web of Science ®Google Scholar
• Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71(1):85–94. doi:10.1016/j.jacc.2017.10.080
   PubMed Web of Science ®Google Scholar
• Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018;15(12):757–769. doi:10.1038/s41569-018-0098-5
   PubMed Web of Science ®Google Scholar
• Takazakura A, Sakurai M, Bando Y, et al. Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy. J Diabetes Investig. 2015;6(3):346–353. doi:10.1111/jdi.12296
   PubMed Web of Science ®Google Scholar
• Shen X, Zhang Z, Zhang X, et al. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2016;15(1):179. doi:10.1186/s12944-016-0350-0
   PubMed Web of Science ®Google Scholar
• Lv J, Ren C, Hu Q. Effect of statins on the treatment of early diabetic nephropathy: a systematic review and meta-analysis of nine randomized controlled trials. Ann Palliat Med. 2021;10(11):11548–11557. doi:10.21037/apm-21-2673
   Web of Science ®Google Scholar
• Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18(11):1018–1028. doi:10.5551/jat.9084
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015;3(3):181–190. doi:10.1016/S2213-8587(14)70246-3
   PubMed Web of Science ®Google Scholar
• Fellström B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int. 2004;66(4):1549–1555. doi:10.1111/j.1523-1755.2004.00919.x
   PubMed Web of Science ®Google Scholar
• Huskey J, Lindenfeld J, Cook T, et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian simvastatin survival study (4S). Atherosclerosis. 2009;205(1):202–206. doi:10.1016/j.atherosclerosis.2008.11.010
   PubMed Web of Science ®Google Scholar
• Haynes R, Lewis D, Emberson J, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25(8):1825–1833. doi:10.1681/ASN.2013090965
   PubMed Web of Science ®Google Scholar
• Su X, Zhang L, Lv J, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67(6):881–892. doi:10.1053/j.ajkd.2016.01.016
   PubMed Web of Science ®Google Scholar
• Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166(17):1884–1891. doi:10.1001/archinte.166.17.1884
   Google Scholar
• Noels H, Lehrke M, Vanholder R, Jankowski J. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol. 2021;17(8):528–542. doi:10.1038/s41581-021-00423-5
   PubMed Web of Science ®Google Scholar
• Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14(8):2084–2091. doi:10.1681/ASN.V1482084
   PubMed Web of Science ®Google Scholar
• Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293–301. doi:10.1046/j.1523-1755.2000.00165.x
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008–2024. doi:10.1001/jama.2015.15629
   PubMed Web of Science ®Google Scholar
• Gai Z, Wang T, Visentin M, Kullak-Ublick GA, Fu X, Wang Z. Lipid accumulation and chronic kidney disease. Nutrients. 2019;11(4):722. doi:10.3390/nu11040722
   PubMed Web of Science ®Google Scholar
• Multi-Disciplinary Expert Task Force on Hyperuricemia and Its Related Diseases. Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases. Chin Med J. 2017;130(20):2473–2488. doi:10.4103/0366-6999.216416
   Web of Science ®Google Scholar
• Joint committee for guideline revision 2016. Chinese guideline for the management of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(10):833–853. doi:10.3760/cma.j.issn.0253-3758.2016.10.005
   Google Scholar
• Jiang S, Huang X, Zhang L, et al. Estimated survival and major comorbidities of very preterm infants discharged against medical advice vs treated with intensive care in China. JAMA Netw Open. 2021;4(6):e2113197. doi:10.1001/jamanetworkopen.2021.13197
   Web of Science ®Google Scholar
• Hu PJ, Wu MY, Lin TC, et al. Effect of statins on renal function in chronic kidney disease patients. Sci Rep. 2018;8(1):16276. doi:10.1038/s41598-018-34632-z
   Web of Science ®Google Scholar
• Cho EY, Myoung C, Park HS, et al. Efficacy of statin treatment in early-stage chronic kidney disease. PLoS One. 2017;12(1):e0170017. doi:10.1371/journal.pone.0170017
   PubMed Web of Science ®Google Scholar
• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–272. doi:10.1016/S0140-6736(13)60687-X
   PubMed Web of Science ®Google Scholar
• Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047. doi:10.1001/jama.298.17.2038
   PubMed Web of Science ®Google Scholar
• Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112(2):171–178. doi:10.1161/CIRCULATIONAHA.104.517565
   PubMed Web of Science ®Google Scholar
• Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the air force/texas coronary atherosclerosis prevention study. Am J Kidney Dis. 2010;55(1):42–49. doi:10.1053/j.ajkd.2009.09.020
   PubMed Web of Science ®Google Scholar
• Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52(3):412–424. doi:10.1053/j.ajkd.2008.05.027
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ofori-Asenso R, Curtis AJ, et al. Association of statin use with disability-free survival and cardiovascular disease among healthy older adults. J Am Coll Cardiol. 2020;76(1):17–27. doi:10.1016/j.jacc.2020.05.016
   Web of Science ®Google Scholar
• Zhou Z, Ryan J, Ernst ME, et al. Effect of statin therapy on cognitive decline and incident dementia in older adults. J Am Coll Cardiol. 2021;77(25):3145–3156. doi:10.1016/j.jacc.2021.04.075
   Web of Science ®Google Scholar
• Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57–70. doi:10.1038/nrneph.2017.155
   PubMed Web of Science ®Google Scholar
• Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88(88):3–11. doi:10.1016/j.phrs.2014.03.002
   Web of Science ®Google Scholar
• Kong Y, Feng W, Zhao X, et al. Statins ameliorate cholesterol-induced inflammation and improve AQP2 expression by inhibiting NLRP3 activation in the kidney. Theranostics. 2020;10(23):10415–10433. doi:10.7150/thno.49603
   PubMed Web of Science ®Google Scholar
• Agarwal R. Effects of statins on renal function. Mayo Clin Proc. 2007;82(11):1381–1390. doi:10.4065/82.11.1381
   PubMed Web of Science ®Google Scholar
• Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14(6):1605–1613. doi:10.1097/01.ASN.0000068461.45784.2F
   PubMed Web of Science ®Google Scholar
• Elisaf M, Mikhailidis DP. Statins and renal function. Angiology. 2002;53(5):493–502. doi:10.1177/000331970205300501
   Web of Science ®Google Scholar
• Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19(6):540–556. doi:10.1185/030079903125002225
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Stone PH, Fayyad RS, Laskey RE, Wilson DJ. Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial. Drugs Aging. 2015;32(12):1055–1065. doi:10.1007/s40266-015-0328-z
   Web of Science ®Google Scholar
• Park F. Activators of G protein signaling in the kidney. J Pharmacol Exp Ther. 2015;353(2):235–245. doi:10.1124/jpet.115.222695
   Web of Science ®Google Scholar
• Tonelli M. Do statins protect the kidney by reducing proteinuria? Ann Intern Med. 2006;145(2):147–149. doi:10.7326/0003-4819-145-2-200607180-00015
   Web of Science ®Google Scholar
• Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(7):695–712. doi:10.1007/s00210-016-1252-4
   PubMed Web of Science ®Google Scholar